La Agencia Española de Medicamentos y Producto Sanitarios (AEMPS) está monitorizando de manera continua con los expertos de las agencias europeas, la EMA y el resto de agencias mundiales todos los datos relativos al uso de medicamentos para tratar la COVID-19. Se trata de... un escenario que puede ir cambiando por la enorme cantidad de datos, comunicaciones y publicaciones que se están generando a nivel mundial. El presente documento técnico tiene la finalidad de guiar el manejoclínicode los pacientes conCOVID-19 con un doble objetivo: lograr el mejor tratamiento del paciente que contribuya a su buena evolución clínica; y garantizar los niveles adecuados de prevención y control de la infección para la protección de los trabajadores sanitarios y de la población en su conjunto.
more
El presente documento técnico tiene la finalidad de guiar el manejode cuidados intensivosde los pacientes conCOVID-19 con undoble objetivo: lograr el mejor tratamiento del paciente que contribuya a subuena evolución clínica; ygarantizar los niveles adecuados de prevención y control de la... infección para la protección de los trabajadores sanitarios y de la población en su conjunto.
more
BUKO Pharma-Kampagne has investigated the causes and consequences of antibiotic resistance in India, South Africa, Tanzania and Germany. Together with our partners we collected data and did interviews with numerous stakeholders. The outcome is presented in a brochure that is now available in English...
Resistant bacteria are spreading worldwide. In collaboration with partners in India, Tanzania, South Africa and Germany, we have investigated the causes and consequences of this spread.2 This Pharma-Brief Special presents the results. It examines the risks for humans, animals and the environment. It focuses on local problems and approaches, international interactions and the re-sponsibility of doctors, farmers and consumers.
more
Updated 10 August 2020
This document presents an essential medicines list (EML) to manage patients in intensive care units (ICUs) with suspected or confirmed COVID-19 diagnosis, which includes active ingredients with dosage form and concentration, and are preferably in the WHO Model Lists of Essent...ial Medicines 2019; based on clinical presentations and symptoms identified and prioritized in World Health Organization (WHO) and Surviving Sepsis Campaign (SSC) guidelines and the evidence presented in these guidelines.
more
WHO published guidance for clinicians and health care decision-makers on the use of corticosteroids in patients with COVID-19.
We recommend systemic corticosteroids for the treatment of patients with severe and critical COVID-19. We suggest not to use corticosteroids in the treatment of patients ...with non-severe COVID-19 as the treatment brought no benefits, and could even prove harmful. Treatment should be under supervision of a clinician.
Corticosteroids are listed in the WHO model list of essential medicines, readily available globally at a low cost. WHO encourages countries to maintain sufficient stocks of corticosteroids to treat COVID-19 and the other disease for which they are effective, while not maintaining excessive stocks which could deny other countries access.
more
Orientação provisória. 2 de setembro de 2020
Questão clínica: Qual é o papel dos corticosteroides sistêmicos no tratamento de pacientes com COVID-19? Público-alvo: O público-alvo consiste principalmente de médicos, seguido por tomadores de decisão na área de saúde.
Estas Pranchas para o diagnóstico microscópico da malária servem como guia para laboratoristas e técnicos de campo responsáveis por diagnóstico microscópico da malária pelo método de Giemsa. Também devem ser úteis para professores e alunos de disciplinas correlatas. As pranchas mostram fo...tomicrografias coloridas de lâminas de sangue (esfregaços e gotas espessas), coradas, e texto explicativo sobre as quatro espécies de parasitos causadores da malária humana e sua morfologia. São fornecidas descrições completas de cada espécie, bem como instruções sobre o preparo de lâminas e esfregaços, o uso de soluções tampão, o método de coloração Giemsa, o exame das lâminas e procedimentos para estimar a densidade parasitária. Nada será adicionado sobre knowlesi e simium? Acho importante até para que as pessoas saibam com o que se parecem. Também são descritos outros elementos celulares observados no sangue, bem como vários contaminantes comuns que podem ser confundidos com parasitos da malária.
more
This update of the Guidelines for poison control, entitled Guidelines for establishing a poison centre, reflects the development of the role of poison centres in public health and the sound management of chemicals, described in section 1, and the opportunities provided by new technology. Assessments... carried out under the IHR show
continuing gaps in capacity for managing chemicals (2). In particular, many countries still lack access to poison
centre services (3). There is therefore demand for updated guidance.
more
OBJETIVO DE LA GUÍA
Describir los lineamientos técnicos de la vigilancia de tuberculosis por el laboratorio, así como los
procesos de obtención, recolección, procesamiento, transporte y conservación de muestras, y las
funciones que se realizan y articulan por todos los integra...ntes de la Red Nacional de Laboratorios.
more
Global Biodiversity Outlook (GBO) is the flagship publication of the Convention on Biological Diversity (CBD). It is a periodic report that summarizes the latest data on the status and trends of biodiversity and draws conclusions relevant to the further implementation of the Convention.
GBO-5 pro...vides global summary of progress towards the Aichi Biodiversity Targets and is based on a range of indicators, research studies and assessments (in particular the IPBES Global Assessment on Biodiversity and Ecosystem Services), as well as the national reports provided by countries on their implementation of the CBD. The national reports provide rich information about the steps taken in countries worldwide in support of biodiversity conservation, sustainable use, and the fair and equitable sharing of benefits. This body of Information provides a wealth of information on the successes and challenges in implementing the Strategic Plan for Biodiversity 2011-2020 and in reaching the Aichi Biodiversity Targets.
This Outlook draws on the lessons learned during the first two decades of this century to clarify the transitions needed if we are to realize the vision agreed by world governments for 2050, ‘Living in Harmony with Nature’.
more
La Perspectiva Mundial sobre la Diversidad Biológica (PMB) es la principal publicación del Convenio sobre la Diversidad Biológica (CDB). Se trata de un informe periódico que resume los datos más recientes sobre la situación y las tendencias de la biodiversidad y extrae conclusiones pertinentes... para la aplicación ulterior del Convenio.
La GBO-5 ofrece un resumen global de los progresos realizados en la consecución de las Metas de Aichi para la Diversidad Biológica y se basa en una serie de indicadores, estudios de investigación y evaluaciones (en particular la Evaluación Mundial de la Diversidad Biológica y los Servicios de los Ecosistemas de la IPBES), así como en los informes nacionales presentados por los países sobre su aplicación del CDB. Los informes nacionales proporcionan una rica información sobre las medidas adoptadas en los países de todo el mundo en apoyo de la conservación de la biodiversidad, el uso sostenible y el reparto justo y equitativo de los beneficios. Este conjunto de información proporciona una gran cantidad de información sobre los éxitos y los desafíos en la aplicación del Plan Estratégico para la Diversidad Biológica 2011-2020 y en la consecución de las Metas de Aichi para la Diversidad Biológica.
Esta Perspectiva se basa en las lecciones aprendidas durante las dos primeras décadas de este siglo para aclarar las transiciones necesarias si queremos hacer realidad la visión acordada por los gobiernos del mundo para 2050, "Vivir en armonía con la naturaleza".
more
The strategic framework gives guidance to public and private health facilities and health workers on compliance with standards relating to IPC practices. To further assist health facilities to implement the IPC strategic framework, this practical implementation manual has been developed in parallel ...to accompany the document.
These implementation strategies should be read in conjunction with the National Infection Prevention and Control (IPC) Strategic Framework (2020) to support an IPC programme at health facility level towards reducing healthcare-associated infections (HAI) and antimicrobial resistance (AMR). This manual is aligned with the World Health Organization (WHO) Core Component IPC programme recommendations and highlights the essentials for developing and improving IPC at health facility level in a systematic, stepwise manner for South Africa. It supports the Framework for the Prevention and Containment of AMR in South African Hospitals (2018).
more